These results suggest that a randomized trial with a larger sample size and a higher dosage of pravastatin would be helpful in further evaluating the anti-inflammatory properties of pravastatin , its association with improvements in cognitive symptoms , and its potential to reduce positive and negative symptoms associated with schizophrenia or schizoaffective disorders .